A market repricing of risk

Across 2024 and into 2025, the life sciences investment landscape has entered a period of rational recalibration. The latest EY Firepower Report shows that large pharmaceutical companies continue to hold record levels of deployable capital, but are now directing it toward smaller, earlier-stage, and strategically aligned transactions, focusing increasingly on precision and innovation-led assets. The focus has shifted from scale to translational clarity, to assets that can integrate seamlessly into existing R&D frameworks.

Meanwhile, Deloitte’s Return on Innovation report highlights a key paradox. While overall R&D productivity has improved, Deloitte estimates that the average cost to bring a new therapy to market remains above $2 billion, underscoring the structural inefficiency and persistently high failure rates of current development models.

The lesson is clear: markets now reward those who can reduce biological uncertainty before reaching the clinic. And that is exactly where Elixion operates.

The economics of certainty

In finance, the cost of risk declines when assumptions are supported by verifiable data, thereby shifting expectations and increasing certainty. The same logic applies to biotechnology.

In silico validation is not just about speed, it is about reducing the volatility of the biological assumptions we are making. When potential therapeutic targets are validated across multiple orthogonal models, the expected probability of success changes fundamentally.

Independent longitudinal analyses, including work led by GSK researchers, show that drug targets supported by human genetic or mechanistic validation are roughly twice as likely to achieve clinical success compared with those without this evidence. Similar outcomes are reported by other research groups that note that model-informed discovery frameworks help eliminate non-viable targets earlier and accelerate proof-of-mechanism studies.

For investors, this represents a valuation inflexion point. Early validation is an intrinsic hedge, moving uncertainty away from the costly wet lab phase to the dry lab, where risk can be measured, tested, and priced more efficiently.

Where quantum physics meets precision medicine

The industry no longer rewards scale or optionality for its own sake; it rewards clarity of mechanism and line-of-sight to human relevance.

At Elixion, we have taken this principle further. By integrating quantum physics-informed modelling alongside multi-omics inference, we simulate molecular interactions from first principles, uncovering causal biological mechanisms that conventional models miss.

Our quantum physics R&D approach is therapeutic area agnostic and is not based on quantum computing. It is a methodology designed to uncover causal precision across any biological system. In aggressive and underserved cancers such as Triple Negative Breast Cancer (TNBC) and HER2-negative breast cancer, biological noise has long obscured causal pathways. TNBC lacks conventional targets (no HER2, oestrogen, or progesterone receptors), leaving little molecular structure to exploit. Elixion’s quantum physics-informed approach reconstructs that structure and has recently demonstrated its capabilities, identifying five causally validated targets that bridge TNBC and HER2-negative subtypes through shared resistance biology and cellular plasticity.

We are now advancing these targets through in vivo validation and into preclinical development. From there, our plan is to expand methodically into additional indications across other therapeutic areas, confirming our approach consistently delivers reproducible and translatable biological insights across multiple disease domains.

This disciplined strategy enables systematic de-risking and diversification, both in indications and partnerships – strengthening the quality of our assets and increasing the net present value of invested capital.

Precision as a catalyst for partnership

In oncology, precision has become a commercial imperative. Targeting treatments to defined patient groups is the only reliable way to improve outcomes, reduce trial failures, and create sustainable value in an increasingly complex and competitive field.

Roche and AstraZeneca publicly emphasise biomarker-driven development as central to their R&D strategies. They are embedding patient stratification and mechanism-based validation across their clinical pipelines, and prioritising investment in assets with these characteristics already defined.

Elixion’s in silico validation generates exactly that: biomarker-defined patient cohorts linked to molecular mechanisms. For TNBC and HER2-negative tumours, this enables trials to be prospectively designed around predicted responders, reducing attrition and accelerating timelines. Precision becomes both a scientific and economic driver of value creation.

A new contract between capital and science

The deal structures shaping today’s life sciences sector reflect a new capital discipline: risk sharing expressed through biology.

In its Morgan Lewis M&A Academy, Morgan Lewis notes that life science companies are increasingly favouring milestone-linked collaborations, structured partnership and acquisition options. An evolution that recognises value is best created and released progressively, as biological evidence accumulates.

Elixion applies this same logic to its financing architecture. Our seed round is structured around three predefined biological gates within a single, fully committed round. Capital is released on achieving each gate.

This model keeps investors closely involved and informed throughout the process (an embedded de-risking mechanism). By balancing shared risk with structured optionality, it allows investors to participate at defined value milestones without speculative exposure. The result is an institutional-grade model built for long-term capital, reflecting the new equilibrium between scientific validation and financial discipline.

That equilibrium defines more than our capital model; it defines our philosophy. The convergence of rational capital allocation, rising R&D costs, and precision medicine has created a new contract between capital and science. A de-risked seed investment is not less ambitious; it is simply front-loaded with proof. Elixion’s five validated targets embody this evolution. They are not hypotheses seeking funding, but validated opportunities positioned for translation.

For investors the value proposition is clear: lower biological volatility, faster proof of mechanism, and a development model that mirrors modern capital deployment.

In financial terms, it is convexity: limited downside with asymmetric upside.

In capital allocation terms, it is the conversion of biological uncertainty into a financeable risk profile.

In scientific terms, it is progress made predictable.

Together, these forces define a new equilibrium between evidence and value creation, where capital efficiency and biological precision converge.

Elixion stands at the intersection of proof and capital discipline, where risk is quantified, progress is priced, and precision itself becomes the source of alpha.

References

• AstraZeneca (2024) Annual Report 2024. AstraZeneca PLC.
• Deloitte (2024) Return on Innovation Report. Deloitte Insights.
• EY (2024) Firepower Report 2024. Ernst & Young Global Limited.
• GSK (2019) King, E.A. et al. Nature. ‘Human genetic evidence supports drug target validation.’
• Morgan Lewis (2025) Morgan Lewis M&A Academy. Morgan, Lewis & Bockius LLP.
• Roche (2023) Annual Report 2023. Roche Holding AG.